October 2, 2024
Owkin, AstraZeneca to develop AI gBRCA pre-screen solution for breast cancer
Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, and AstraZeneca, have teamed up to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitised pathology slides.